Welcome to our dedicated page for Windtree Therapeutics SEC filings (Ticker: WINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Windtree Therapeutics, Inc. (WINT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain complex documents. Windtree continues to file current reports on Form 8-K, registration statements on Form S-1, proxy statements on Schedule 14A and notifications of late filing on Form 12b-25, giving investors insight into its financing arrangements, capital structure, listing status and strategic decisions.
For WINT, several 8-K filings detail senior convertible promissory notes and commitment notes issued to institutional investors. These filings describe interest rates, maturity dates, conversion prices tied to recent trading prices, beneficial ownership limits, anti-dilution provisions, prepayment obligations linked to equity financings and rights in the event of fundamental transactions. AI summaries can highlight how these terms may affect potential dilution, liquidity and the company’s ability to raise capital.
Other key filings include 8-K reports on the termination of a cardiogenic shock clinical study of istaroxime, settlement of a disputed real estate purchase agreement, and a Nasdaq delisting notice explaining the transition of WINT trading from the Nasdaq Capital Market to the over-the-counter market. Form 12b-25 notifications outline reasons for delayed quarterly reports and, in one case, provide preliminary estimates of a significant change in net loss driven by impairment and debt issuance accounting. The company’s S-1 registration statement and definitive proxy statement describe its equity structure, preferred stock series, warrants, equity line of credit and proposals to increase authorized shares and effect a reverse stock split.
On this page, AI tools can help you quickly understand the main points of lengthy 10-Q, 10-K, S-1 and 8-K filings, flag important sections on convertible securities, impairment charges, listing status and clinical program changes, and surface Form 4 insider transaction data when available. Real-time updates from EDGAR ensure that new Windtree filings, amendments and exhibits are added promptly, so you can review both the raw documents and concise explanations before making your own assessments about WINT.
Windtree Therapeutics (NASDAQ:WINT) filed an 8-K disclosing three material events dated June 24-25, 2025.
- $150,000 raised via two 14% convertible promissory notes (12-month maturity, $0.587 conversion price) plus warrants covering 75% of each investment.
- Seller TBB Crescent Park Drive LLC terminated a Texas real-estate purchase; it demands release of $3 million earnest money paid by Way Maker and Windtree, which the company is disputing.
- CFO Jamie McAndrew resigned effective June 25; CEO Jed Latkin will serve as interim principal financial officer.
The notes and warrants were issued under Rule 506(b) exemptions and proceeds will fund operations. The property dispute could create a cash outflow materially larger than the new financing, and management turnover raises governance concerns.
Windtree Therapeutics (WINT) has received a Nasdaq deficiency notice on June 18, 2025, for failing to maintain the minimum bid price requirement of $1.00 per share over the last 30 consecutive business days.
Unlike standard cases where companies receive a 180-day compliance period, Windtree faces immediate delisting risk due to two key factors:
- The company is under a Discretionary Panel Monitor until March 20, 2026
- It has conducted two reverse stock splits in the past two years with a cumulative ratio exceeding 250:1, making it ineligible for the standard compliance period
Windtree plans to request a hearing before the Nasdaq Hearings Panel by June 25, 2025, which will automatically stay any suspension/delisting action. The company's stock continues trading on Nasdaq Capital Market under "WINT" symbol, though there is no guarantee of maintaining the listing or regaining compliance.